CTLA4 and melanoma: The IPS profile differs between melanoma patients who respond or do not respond to immune checkpoint blockade (ICB) therapy (for anti-PD-1 and anti-CTLA-4), posing clear potential implications of this algorithm as a response predictor tool to immunotherapy 40.